{
  "trx_id": "617d3fcb11f8afc2005f49a06d512018c6c9df0a",
  "block": 106151293,
  "trx_in_block": 1,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2026-05-18T06:49:06",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "7116.371212 VESTS"
    }
  ]
}

{
  "trx_id": "f24acce2cc52d2a4e648f4b4f913bad42199efd4",
  "block": 106007669,
  "trx_in_block": 5,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2026-05-13T06:32:03",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "4404.160807 VESTS"
    }
  ]
}

{
  "trx_id": "715a30c1bc7f064a3e8ba5abeb8a35db3eca0514",
  "block": 105518762,
  "trx_in_block": 0,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2026-04-26T06:00:06",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "7128.886968 VESTS"
    }
  ]
}

{
  "trx_id": "cc40c77fcf66d00b178edfdec55c385cfceb04d2",
  "block": 102872992,
  "trx_in_block": 4,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2026-01-24T01:29:03",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "4445.707626 VESTS"
    }
  ]
}

{
  "trx_id": "4f28971262135029334326b8f1366eb0d709b986",
  "block": 91319197,
  "trx_in_block": 2,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2024-12-17T20:38:30",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "4609.926823 VESTS"
    }
  ]
}

{
  "trx_id": "57ea8bb365e26703d0abb733b33322e6d56339f0",
  "block": 79873326,
  "trx_in_block": 13,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2023-11-14T12:18:54",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "4779.060355 VESTS"
    }
  ]
}

{
  "trx_id": "fcba6df63658c40852678e3a2d8d2515be20b692",
  "block": 78363626,
  "trx_in_block": 4,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2023-09-22T11:01:39",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "7715.969141 VESTS"
    }
  ]
}

{
  "trx_id": "0ecb205f92f87e6e91d830aac22b48af89652bb8",
  "block": 69121268,
  "trx_in_block": 13,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2022-11-03T18:24:27",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "7938.020579 VESTS"
    }
  ]
}

{
  "trx_id": "1046fc9823e01f1935fc503178acc78eb5194bec",
  "block": 60824454,
  "trx_in_block": 12,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2022-01-17T23:33:09",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "8158.128180 VESTS"
    }
  ]
}

{
  "trx_id": "69ba0b2e6edcfd3084f44862f7c517ecfa5080c0",
  "block": 54614748,
  "trx_in_block": 10,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2021-06-14T06:42:33",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "8342.322468 VESTS"
    }
  ]
}

{
  "trx_id": "c6b1c78c251d6453a886def134506770f204c126",
  "block": 49361995,
  "trx_in_block": 1,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2020-12-11T16:54:21",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "8529.744442 VESTS"
    }
  ]
}

{
  "trx_id": "20e62656a0670c48f659dfcc0495d754388f988f",
  "block": 49213506,
  "trx_in_block": 2,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2020-12-06T10:29:42",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "1912.543513 VESTS"
    }
  ]
}

{
  "trx_id": "7b06079ce16660a14334f1214a08fe39d7763027",
  "block": 49197080,
  "trx_in_block": 2,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2020-12-05T20:32:12",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "8535.952296 VESTS"
    }
  ]
}

{
  "trx_id": "b139ac8d4579fc23f9be36dd800f5e471067b4eb",
  "block": 48271985,
  "trx_in_block": 2,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2020-11-03T03:41:12",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "1920.017158 VESTS"
    }
  ]
}

{
  "trx_id": "14680105a33777b7335b226e62d8e1a9dcdb0a9a",
  "block": 43223848,
  "trx_in_block": 10,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2020-05-09T11:33:27",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "8738.757655 VESTS"
    }
  ]
}

{
  "trx_id": "94e304cc1203f7ca0a09c59ec30f1a62f2d8e9f6",
  "block": 43200969,
  "trx_in_block": 11,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2020-05-08T16:01:39",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "1953.311140 VESTS"
    }
  ]
}

{
  "trx_id": "e50ac84f9a3a40b6316149f52e285e37df74de23",
  "block": 41491515,
  "trx_in_block": 10,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2020-03-09T04:49:42",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "8770.289156 VESTS"
    }
  ]
}

{
  "trx_id": "152538a649a7087661cf5561b5c8c7fd9e4c625c",
  "block": 38036906,
  "trx_in_block": 6,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2019-11-09T23:29:24",
  "op": [
    "comment",
    {
      "parent_author": "squirrelnv",
      "parent_permlink": "cisco-s-maciej-kranz-on-iot-itbra-cyrcadia",
      "author": "steemitboard",
      "permlink": "steemitboard-notify-squirrelnv-20191109t232924000z",
      "title": "",
      "body": "Congratulations @squirrelnv! You received a personal award!\n\n<table><tr><td>https://steemitimages.com/70x70/http://steemitboard.com/@squirrelnv/birthday2.png</td><td>Happy Birthday! - You are on the Steem blockchain for 2 years!</td></tr></table>\n\n<sub>_You can view [your badges on your Steem Board](https://steemitboard.com/@squirrelnv) and compare to others on the [Steem Ranking](https://steemitboard.com/ranking/index.php?name=squirrelnv)_</sub>\n\n\n**Do not miss the last post from @steemitboard:**\n<table><tr><td><a href=\"https://steemit.com/steemfest/@steemitboard/steemfest-meet-the-stemians-contest-the-mysterious-rule-revealed\"><img src=\"https://steemitimages.com/64x128/https://cdn.steemitimages.com/DQmasWw4jQHwxng82DKxY6Q6tVg9mWcto4xcDURs8knFgCa/image.png\"></a></td><td><a href=\"https://steemit.com/steemfest/@steemitboard/steemfest-meet-the-stemians-contest-the-mysterious-rule-revealed\">SteemFest Meet The Stemians Contest - The mysterious rule revealed</a></td></tr><tr><td><a href=\"https://steemit.com/steemfest/@steemitboard/steemfest-meet-the-steemians-contest\"><img src=\"https://steemitimages.com/64x128/https://cdn.steemitimages.com/DQmasWw4jQHwxng82DKxY6Q6tVg9mWcto4xcDURs8knFgCa/image.png\"></a></td><td><a href=\"https://steemit.com/steemfest/@steemitboard/steemfest-meet-the-steemians-contest\">SteemFest⁴  - Meet the Steemians Contest</a></td></tr></table>\n\n###### [Vote for @Steemitboard as a witness](https://v2.steemconnect.com/sign/account-witness-vote?witness=steemitboard&approve=1) to get one more award and increased upvotes!",
      "json_metadata": "{\"image\":[\"https://steemitboard.com/img/notify.png\"]}"
    }
  ]
}

{
  "trx_id": "28dd27df13958e3052bfe7ed12d54342bfc5295e",
  "block": 31910337,
  "trx_in_block": 2,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2019-04-10T02:09:30",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "8966.264479 VESTS"
    }
  ]
}

{
  "trx_id": "af94fca263d12c882077354705dcf76812304e05",
  "block": 29288997,
  "trx_in_block": 0,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2019-01-08T23:43:27",
  "op": [
    "comment",
    {
      "parent_author": "squirrelnv",
      "parent_permlink": "cisco-s-maciej-kranz-on-iot-itbra-cyrcadia",
      "author": "steemitboard",
      "permlink": "steemitboard-notify-squirrelnv-20190108t234326000z",
      "title": "",
      "body": "Congratulations @squirrelnv! You have completed the following achievement on the Steem blockchain and have been rewarded with new badge(s) :\n\n<table><tr><td>https://steemitimages.com/60x70/http://steemitboard.com/@squirrelnv/votes.png?201901082103</td><td>You made more than 50 upvotes. Your next target is to reach 100 upvotes.</td></tr>\n</table>\n\n<sub>_[Click here to view your Board](https://steemitboard.com/@squirrelnv)_</sub>\n<sub>_If you no longer want to receive notifications, reply to this comment with the word_ `STOP`</sub>\n\n\n\n**Do not miss the last post from @steemitboard:**\n<table><tr><td><a href=\"https://steemit.com/steem/@steemitboard/steemwhales-has-officially-moved-to-steemitboard-ranking\"><img src=\"https://steemitimages.com/64x128/https://cdn.steemitimages.com/DQmfRVpHQhLDhnjDtqck8GPv9NPvNKPfMsDaAFDE1D9Er2Z/header_ranking.png\"></a></td><td><a href=\"https://steemit.com/steem/@steemitboard/steemwhales-has-officially-moved-to-steemitboard-ranking\">SteemWhales has officially moved to SteemitBoard Ranking</a></td></tr><tr><td><a href=\"https://steemit.com/steemitboard/@steemitboard/steemitboard-witness-update-2019-01-07\"><img src=\"https://steemitimages.com/64x128/http://i.cubeupload.com/7CiQEO.png\"></a></td><td><a href=\"https://steemit.com/steemitboard/@steemitboard/steemitboard-witness-update-2019-01-07\">SteemitBoard - Witness Update</a></td></tr></table>\n\n> Support [SteemitBoard's project](https://steemit.com/@steemitboard)! **[Vote for its witness](https://v2.steemconnect.com/sign/account-witness-vote?witness=steemitboard&approve=1)** and **get one more award**!",
      "json_metadata": "{\"image\":[\"https://steemitboard.com/img/notify.png\"]}"
    }
  ]
}

{
  "trx_id": "244bb3f5d1bd1c1dd4e0c237ec793f74f2fbff36",
  "block": 29283889,
  "trx_in_block": 3,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2019-01-08T19:27:57",
  "op": [
    "vote",
    {
      "voter": "squirrelnv",
      "author": "muddywater33",
      "permlink": "cyrcadia-health",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "0000000000000000000000000000000000000000",
  "block": 29258943,
  "trx_in_block": 4294967295,
  "op_in_trx": 0,
  "virtual_op": 10,
  "timestamp": "2019-01-07T22:39:57",
  "op": [
    "author_reward",
    {
      "author": "squirrelnv",
      "permlink": "re-muddywater33-re-muddywater33-cyracadia-health-20181231t223954091z",
      "sbd_payout": "0.000 SBD",
      "steem_payout": "0.110 STEEM",
      "vesting_payout": "225.039820 VESTS"
    }
  ]
}

{
  "trx_id": "900539f931f98a02bc05c5f672c24a0f2b1f2c54",
  "block": 29067140,
  "trx_in_block": 16,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2019-01-01T06:37:51",
  "op": [
    "comment",
    {
      "parent_author": "squirrelnv",
      "parent_permlink": "cisco-s-maciej-kranz-on-iot-itbra-cyrcadia",
      "author": "steemitboard",
      "permlink": "steemitboard-notify-squirrelnv-20190101t063753000z",
      "title": "",
      "body": "Congratulations @squirrelnv! You have completed the following achievement on the Steem blockchain and have been rewarded with new badge(s) :\n\n<table><tr><td>https://steemitimages.com/60x60/http://steemitboard.com/notifications/firstcommented.png</td><td>You got a First Reply</td></tr>\n</table>\n\n<sub>_[Click here to view your Board](https://steemitboard.com/@squirrelnv)_</sub>\n<sub>_If you no longer want to receive notifications, reply to this comment with the word_ `STOP`</sub>\n\n\n\n> Support [SteemitBoard's project](https://steemit.com/@steemitboard)! **[Vote for its witness](https://v2.steemconnect.com/sign/account-witness-vote?witness=steemitboard&approve=1)** and **get one more award**!",
      "json_metadata": "{\"image\":[\"https://steemitboard.com/img/notify.png\"]}"
    }
  ]
}

{
  "trx_id": "a97201ee460a3bdc55d7a9c9faf543c7da8572b4",
  "block": 29062568,
  "trx_in_block": 8,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2019-01-01T02:48:57",
  "op": [
    "comment",
    {
      "parent_author": "muddywater33",
      "parent_permlink": "re-squirrelnv-re-muddywater33-re-muddywater33-cyracadia-health-20190101t005343072z",
      "author": "squirrelnv",
      "permlink": "re-muddywater33-re-squirrelnv-re-muddywater33-re-muddywater33-cyracadia-health-20190101t024855259z",
      "title": "",
      "body": "I came here for Change's info originally too. There was that Cyrcadia Qtr 3 report that we were all curious to see - plus, the deleting thing was happening at that time too. Well, we'll just put the info wherever we can and that's about all we can do. At least everything positive won't be erased by a handful of people here. Hope and pray that 2019 will just quiet all the doubters. Happy New Year, Muddy Brogger!",
      "json_metadata": "{\"tags\":[\"i\"],\"app\":\"steemit/0.1\"}"
    }
  ]
}

{
  "trx_id": "acb8f00d77add9650e3b7561adea27a4720d7d9d",
  "block": 29060297,
  "trx_in_block": 3,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2019-01-01T00:55:18",
  "op": [
    "comment",
    {
      "parent_author": "squirrelnv",
      "parent_permlink": "re-muddywater33-re-muddywater33-cyracadia-health-20181231t223954091z",
      "author": "muddywater33",
      "permlink": "re-squirrelnv-re-muddywater33-re-muddywater33-cyracadia-health-20190101t005343072z",
      "title": "",
      "body": "@@ -119,16 +119,17 @@\n seem cyr\n+a\n cadia do\n@@ -146,16 +146,21 @@\n re news \n+often\n , maybe \n",
      "json_metadata": "{\"tags\":[\"i\"],\"app\":\"steemit/0.1\"}"
    }
  ]
}

{
  "trx_id": "8250a34ce93a8fbd6d57facf489f968a4f0fea06",
  "block": 29060265,
  "trx_in_block": 12,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2019-01-01T00:53:42",
  "op": [
    "comment",
    {
      "parent_author": "squirrelnv",
      "parent_permlink": "re-muddywater33-re-muddywater33-cyracadia-health-20181231t223954091z",
      "author": "muddywater33",
      "permlink": "re-squirrelnv-re-muddywater33-re-muddywater33-cyracadia-health-20190101t005343072z",
      "title": "",
      "body": "Yes, I see that you have tried. Originally i was following change and voo but they have are not been around. It would seem cyrcadia does not share news , maybe because they are not a public company. Wish you luck in the new year! Your correct with the new moderators they seem to be vigilante's against stock scams. they picked the wrong company.",
      "json_metadata": "{\"tags\":[\"i\"],\"app\":\"steemit/0.1\"}"
    }
  ]
}

{
  "trx_id": "540a851da6839d0f3149e7196ae47dd9f4f395bd",
  "block": 29059909,
  "trx_in_block": 19,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2019-01-01T00:35:51",
  "op": [
    "vote",
    {
      "voter": "gentlebot",
      "author": "squirrelnv",
      "permlink": "re-muddywater33-re-muddywater33-cyracadia-health-20181231t223954091z",
      "weight": 1500
    }
  ]
}

{
  "trx_id": "aecb56a2f5191b861499c1169759c1d17a2d99bf",
  "block": 29058259,
  "trx_in_block": 31,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-12-31T23:13:15",
  "op": [
    "custom_json",
    {
      "required_auths": [],
      "required_posting_auths": [
        "squirrelnv"
      ],
      "id": "follow",
      "json": "[\"reblog\",{\"account\":\"squirrelnv\",\"author\":\"muddywater33\",\"permlink\":\"cyracadia-health\"}]"
    }
  ]
}

{
  "trx_id": "25087560ff99f8fbc9e7b4a64cc02d4c5b78a44e",
  "block": 29057733,
  "trx_in_block": 8,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-12-31T22:46:54",
  "op": [
    "vote",
    {
      "voter": "squirrelnv",
      "author": "muddywater33",
      "permlink": "cyracadia-health-using-artificial-intelligence-for-breast-cancer-detection",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "3322b96a8a91593184506b362253fdcb2a1dc608",
  "block": 29057594,
  "trx_in_block": 9,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-12-31T22:39:57",
  "op": [
    "comment",
    {
      "parent_author": "muddywater33",
      "parent_permlink": "re-muddywater33-cyracadia-health-20181231t211143803z",
      "author": "squirrelnv",
      "permlink": "re-muddywater33-re-muddywater33-cyracadia-health-20181231t223954091z",
      "title": "",
      "body": "Thank YOU. Now I can connect the face to the name - or the name to the name. I'm another squirrel on there - SquirrelCage. I was thinking to avoid the deleters - or should I say some \"moderators\" - we should come here. It's just hard to get IHub onlookers to make the switch or people researching the stock to look for information here.",
      "json_metadata": "{\"tags\":[\"i\"],\"app\":\"steemit/0.1\"}"
    }
  ]
}

{
  "trx_id": "058dac2a2274683e09f320b2b1bfae8b1df4fd40",
  "block": 29055859,
  "trx_in_block": 3,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-12-31T21:13:09",
  "op": [
    "vote",
    {
      "voter": "muddywater33",
      "author": "squirrelnv",
      "permlink": "cisco-s-maciej-kranz-on-iot-itbra-cyrcadia",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "3c46f8ccd4394853da039a9d1d3147fd7c2a752e",
  "block": 28969357,
  "trx_in_block": 13,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-12-28T21:05:45",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "29128.406342 VESTS"
    }
  ]
}

{
  "trx_id": "979d2f0b54e8763271e9be4fdea3dd89133cdf7e",
  "block": 28967373,
  "trx_in_block": 11,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-12-28T19:26:30",
  "op": [
    "vote",
    {
      "voter": "squirrelnv",
      "author": "muddywater33",
      "permlink": "cyracadia-health",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "1ddae829ff7dd6a562888cdd39e11e3aa80caa97",
  "block": 28737029,
  "trx_in_block": 4,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-12-20T19:24:33",
  "op": [
    "vote",
    {
      "voter": "squirrelnv",
      "author": "deepthim",
      "permlink": "re-xplore-itbra-early-cancer-detection-via-a-bra-20180913t113835043z",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "638328000745bf35de2133111846a507ed5c4fbf",
  "block": 28420067,
  "trx_in_block": 12,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-12-09T19:04:36",
  "op": [
    "vote",
    {
      "voter": "squirrelnv",
      "author": "xplore",
      "permlink": "itbra-early-cancer-detection-via-a-bra",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "3a88a511f8b9db1dfbffc62d30f417fd6fa3a394",
  "block": 28046427,
  "trx_in_block": 31,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-11-26T19:34:18",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "9042.632115 VESTS"
    }
  ]
}

{
  "trx_id": "c94f60602eea3fa21bb4c9bfdb8b41831f2e47fd",
  "block": 27561578,
  "trx_in_block": 7,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-11-09T23:17:45",
  "op": [
    "comment",
    {
      "parent_author": "squirrelnv",
      "parent_permlink": "cisco-s-maciej-kranz-on-iot-itbra-cyrcadia",
      "author": "steemitboard",
      "permlink": "steemitboard-notify-squirrelnv-20181109t231745000z",
      "title": "",
      "body": "Congratulations @squirrelnv! You have received a personal award!\n\n[![](https://steemitimages.com/70x70/http://steemitboard.com/@squirrelnv/birthday1.png)](http://steemitboard.com/@squirrelnv)  1 Year on Steemit\n<sub>_Click on the badge to view your Board of Honor._</sub>\n\n\n**Do not miss the last post from @steemitboard:**\n<table><tr><td><a href=\"https://steemit.com/steemfest/@steemitboard/steemfest3-and-steemitboard-meet-the-steemians-contest\"><img src=\"https://steemitimages.com/64x128/https://cdn.steemitimages.com/DQmeLukvNFRsa7RURqsFpiLGEZZD49MiU52JtWmjS5S2wtW/image.png\"></a></td><td><a href=\"https://steemit.com/steemfest/@steemitboard/steemfest3-and-steemitboard-meet-the-steemians-contest\">SteemFest3 and SteemitBoard - Meet the Steemians Contest</a></td></tr></table>\n\n> Support [SteemitBoard's project](https://steemit.com/@steemitboard)! **[Vote for its witness](https://v2.steemconnect.com/sign/account-witness-vote?witness=steemitboard&approve=1)** and **get one more award**!",
      "json_metadata": "{\"image\":[\"https://steemitboard.com/img/notify.png\"]}"
    }
  ]
}

{
  "trx_id": "92be10afc22b325507f0ab450573f4366326add4",
  "block": 26895528,
  "trx_in_block": 49,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-10-17T19:50:42",
  "op": [
    "vote",
    {
      "voter": "squirrelnv",
      "author": "muddywater33",
      "permlink": "breast-cancer-awareness-month",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "53f169af302b0668aa8178b6189e5981dbab37d1",
  "block": 25402949,
  "trx_in_block": 20,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-08-26T10:08:42",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "29332.364130 VESTS"
    }
  ]
}

{
  "trx_id": "8e521b43519a9e780bff38799bc07eea24be13fa",
  "block": 24696672,
  "trx_in_block": 8,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-08-01T21:20:57",
  "op": [
    "vote",
    {
      "voter": "squirrelnv",
      "author": "muddywater33",
      "permlink": "little-company-but-huge-for-woman",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "59d8d37c096a81ed4cb90005e6192ff7e46b945a",
  "block": 24186065,
  "trx_in_block": 21,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-07-15T03:11:48",
  "op": [
    "vote",
    {
      "voter": "council",
      "author": "squirrelnv",
      "permlink": "cisco-s-maciej-kranz-on-iot-itbra-cyrcadia",
      "weight": 1000
    }
  ]
}

{
  "trx_id": "d1e75b5548eb6a880611ab359385b882d0a95f18",
  "block": 24185410,
  "trx_in_block": 8,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-07-15T02:39:03",
  "op": [
    "comment",
    {
      "parent_author": "squirrelnv",
      "parent_permlink": "cisco-s-maciej-kranz-on-iot-itbra-cyrcadia",
      "author": "cheetah",
      "permlink": "cheetah-re-squirrelnvcisco-s-maciej-kranz-on-iot-itbra-cyrcadia",
      "title": "",
      "body": "Hi! I am a robot. I just upvoted you! I found similar content that readers might be interested in:\nhttps://newsroom.cisco.com/feature-content?articleId=1888131",
      "json_metadata": ""
    }
  ]
}

{
  "trx_id": "769ffaf98ac5e24c06b5db411442255316cf03db",
  "block": 24185408,
  "trx_in_block": 49,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-07-15T02:38:57",
  "op": [
    "vote",
    {
      "voter": "cheetah",
      "author": "squirrelnv",
      "permlink": "cisco-s-maciej-kranz-on-iot-itbra-cyrcadia",
      "weight": 8
    }
  ]
}

{
  "trx_id": "3091162b7fe0d59ace4e7285cf0b8301c322cf2a",
  "block": 24185405,
  "trx_in_block": 3,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-07-15T02:38:48",
  "op": [
    "comment",
    {
      "parent_author": "",
      "parent_permlink": "iot",
      "author": "squirrelnv",
      "permlink": "cisco-s-maciej-kranz-on-iot-itbra-cyrcadia",
      "title": "Cisco's Maciej Kranz on IoT, iTbra, Cyrcadia",
      "body": "https://www.nerdjunkie.com/blog/2017/10/22/meet-the-exec-maciej-kranz/\n\n\nNews From Cisco \n\n\nMeet the Exec: Maciej Kranz \n\nMaciej Kranz:  I’ve been at Cisco for 18 ½ years and have seen that every few years we face a major technology or business transition. Right now, we as a company and the entire industry face many across-the-board disruptions. So we need to anticipate, proactively address and even drive such transitions and continually find better ways to meet customer needs. Which is why, innovation is not an add-on. It is an essential element of our strategy and culture, an essential part of our DNA. Innovation is happening in every function at Cisco and part of my group’s mission is to continually instill a mindset of innovation across the company.\n\nFocus Magazine:  You are responsible for bringing big ideas to life. Can you explain how you do that?\n\nMaciej Kranz:  My team focuses on three areas. The first one is incubating new businesses in something we call “white spaces.” When we spot an area that could be a market transition, or new technology that could revolutionize any part of Cisco’s business, we assign our top business and technical talent to research this area with other experts. Then, we start building prototypes to get hands-on experience, eventually developing business cases, and finally we work cross-functionally with other Cisco teams to incubate these businesses.\n\nSecondly, we co-innovate with customers and partners via Cisco’s network of global Innovation Centers. Most large companies have “innovation centers,” but often these serve as technology or solution showcases, R&D facilities or seminar spaces for lectures and education. Cisco Innovation Centers have a single mission: bring together governments, customers, partners, local startups, and academia as well as our business units and services teams to co-innovate scalable solutions to business problems. By working with customers and partners in the geographic regions where they are based, we can be both global and hyperlocal. We can co-innovate solutions based on horizontal technologies that address specific local requirements.\n\nFinally, we’re enabling Cisco employees to become entrepreneurs by building a startup culture internally. This seems like an oxymoron, but as a large corporation with 70,000 employees, we do need robust and streamlined processes. However, to thrive in a world that is constantly changing, we also need to instill a startup mindset and entrepreneurial skills across every function. We need to nurture creative thinking, which in turn can lead to dozens of new solution and business ideas. What’s amazing about such efforts is that they bring our employees together in a truly cross-functional, company-wide experience. It’s really the best of both worlds – combining the resources of a big company with the entrepreneurial mindset of a startup.\n\nWe’re now in our third year of the Innovate Everywhere Challenge. In the last two years, more than half of all Cisco employees participated in the challenge and about 2,000 startup ventures were submitted. After refinement, now more than a dozen of these ideas are in various stages of implementation and monetization internally and with external customers. The amazing thing is that these ideas came from virtually every function. Some were pure business concepts, some technology solutions, while others focused on process improvements. As just one example, Team LifeChanger combined collaboration tools with specialized audio and visual devices to help the disabled work remotely. Cisco uses the solution now, many customers are considering it, and it’s been adapted to the Cisco Networking Academy program.\n\nFocus Magazine:  You literally wrote the book on the Internet of Things. Why is IoT so critical to businesses?\n\nThe impact of IoT is already profound as the data generated by devices not only makes businesses more efficient in the short-term, but also transforms them in the long-term with new value propositions, new markets and new business models. Maciej Kranz:  IoT is effectively the next wave of the Internet where every device is connected. The impact of IoT is already profound as the data generated by devices not only makes businesses more efficient in the short-term, but also transforms them in the long-term with new value propositions, new markets and new business models. Increasingly, IoT is becoming the foundation for other transformative technologies including fog computing (distributed cloud), blockchain, artificial intelligence (AI), and more.\n\nWhat excites me is not only the vision, but the journey getting there. I firmly believe that anyone can have a great idea, but few people actually have the opportunity to turn it into a game-changer. I’m fortunate because I’ve experienced both.\n\nFocus Magazine:  You can use IoT to improve just about any industry—but let’s talk about healthcare. How important is IoT to healthcare?\n\nMaciej Kranz: Most IoT implementations today focus on improving efficiency and profitability in the business-to-business environments. But what makes IoT so compelling in healthcare is that it can actually improve quality of life and even save lives.\n\nIoT is already helping us have longer, healthier lives and better care for our loved ones. For example, by connecting TelePresence, collaboration tools and medical devices we can open up new possibilities for remote office visits, diagnostics, and real-time monitoring of serious conditions, which lowers costs, speeds recovery and increases convenience.\n\nRecently, Cisco sponsored the documentary called Detected. It tells the story of the iTBra, an application of IoT and AI that revolutionizes early detection of breast cancer. This has the possibility of saving tens of thousands of women’s lives each year. The wearable, compared with mammograms is a more comfortable and private way to monitor for breast cancer. It contains 16 sensors that monitor and detect changes in breast tissue. After wearing the device for a couple of hours, the data is analyzed through predictive analytics (AI) and the results are sent directly to a woman’s doctor for analysis.\n\n\n\nFocus Magazine:  What originally got you interested in IoT?\n\nMaciej Kranz:  Having seen the initial explosion of commercial Internet in the 1990s, I knew that at some point we would move beyond connecting computers and smartphones. IoT was the promise of every device being connected for incredible benefits. It was the once-in-the-lifetime opportunity to kick-start the next wave of the internet and to transform virtually every industry. It was just too attractive not to jump in with both feet.\n\nFocus Magazine:  What do you think would surprise people about you?\n\nMaciej Kranz : I have four children and an amazing wife. Even though technology is prominent in my job and everyday life, my focus has always been on people, teams and relationships.",
      "json_metadata": "{\"tags\":[\"iot\",\"cisco\",\"cyrcadia\",\"health\",\"llbo\"],\"links\":[\"https://www.nerdjunkie.com/blog/2017/10/22/meet-the-exec-maciej-kranz/\"],\"app\":\"steemit/0.1\",\"format\":\"markdown\"}"
    }
  ]
}

{
  "trx_id": "9cc640d4100fd95c2eeef42d8a1de3533ffef2e6",
  "block": 23764130,
  "trx_in_block": 19,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-06-30T03:15:27",
  "op": [
    "vote",
    {
      "voter": "fastresteem",
      "author": "squirrelnv",
      "permlink": "cyrcadia-health-new-board-member-news",
      "weight": 100
    }
  ]
}

{
  "trx_id": "531abf51cfd29902a289c6243834fe6218c91d68",
  "block": 23764126,
  "trx_in_block": 22,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-06-30T03:15:15",
  "op": [
    "comment",
    {
      "parent_author": "",
      "parent_permlink": "cyrcadia",
      "author": "squirrelnv",
      "permlink": "cyrcadia-health-new-board-member-news",
      "title": "Cyrcadia Health New Board Member News",
      "body": "http://cyrcadiahealth.com/reno-nv-june-12-2018-cyrcadia-inc-new-member-of-board-of-directors/",
      "json_metadata": "{\"tags\":[\"cyrcadia\",\"health\",\"llbo\",\"lifeline\",\"biotech\"],\"links\":[\"http://cyrcadiahealth.com/reno-nv-june-12-2018-cyrcadia-inc-new-member-of-board-of-directors/\"],\"app\":\"steemit/0.1\",\"format\":\"markdown\"}"
    }
  ]
}

{
  "trx_id": "2fecd7c0903605c01a1559c81884bdf475758bd6",
  "block": 23579679,
  "trx_in_block": 2,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-06-23T17:29:12",
  "op": [
    "comment",
    {
      "parent_author": "",
      "parent_permlink": "cyrcadia",
      "author": "squirrelnv",
      "permlink": "cisco-maciej-kranz-discussing-iot-and-itbra-detected",
      "title": "Cisco Maciej Kranz Discussing IoT and iTbra/Detected",
      "body": "https://video.cisco.com/detail/video/5776123717001/maciej-kranz-discusses-iot-and-revolutionary-tech?autoStart=true&q=itbra",
      "json_metadata": "{\"tags\":[\"cyrcadia\",\"health\",\"llbo\",\"cisco\",\"detected\"],\"links\":[\"https://video.cisco.com/detail/video/5776123717001/maciej-kranz-discusses-iot-and-revolutionary-tech?autoStart=true&q=itbra\"],\"app\":\"steemit/0.1\",\"format\":\"markdown\"}"
    }
  ]
}

{
  "trx_id": "6d972bb33c3e44e5d334eaa82adccba85068a901",
  "block": 22857835,
  "trx_in_block": 44,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-05-29T15:18:21",
  "op": [
    "vote",
    {
      "voter": "bunmipaul",
      "author": "squirrelnv",
      "permlink": "cyrcadia-health-ai-advancements",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "946aa60cc879250a9d8ec25a60aa7f66e26de640",
  "block": 22857827,
  "trx_in_block": 17,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-05-29T15:17:57",
  "op": [
    "comment",
    {
      "parent_author": "",
      "parent_permlink": "cyrcadia",
      "author": "squirrelnv",
      "permlink": "cyrcadia-health-ai-advancements",
      "title": "Cyrcadia Health AI Advancements",
      "body": "http://cyrcadiahealth.com/may-14-2018-reno-nv-artificial-intelligence-advancements/\n\nNew discoveries have been achieved with our artificial intelligence (AI) algorithms. Recalling the foundational basis for the Cyrcadia Health intellectual property and patent filings is five algorithms that analyze tissue temperature and circadian body rhythm disruptions over a time period (dynamic) to identify tissue abnormalities. “Recently, our AI software scientists have made new discoveries that will bring additional value to our users who want to understand their health condition”, says Matt Benardis, CEO.\n\nAdvanced data analysis and formula modification has achieved three goals:\n1. The science of ability to locate a tissue liesion abnormality location has now been verified. This means a doctor will know where to start more advanced therapies. Location is significant, as this will allow the physician to focus on a specific area for further investigation. With additional data from our clinical studies, we can advance our tissue knowledge without having to re-engineer our device and sensors.\n2. A new Wellness score can be computed based on metabolic patterns that can be used to begin tracking behaviors on the basis of clinical trial data.\n3. Wear time can now be as little as two hours. Analysis of datasets has detected the same statistical probability in a two hour dataset as in an 8 hour dataset. This means the Circadian disruption is perpetuated throughout the circadian cycle, leaving a detectable “signature”. This signature means the metabolic behavior can be identified for continued observation. Our four clinical trials continue to show the same successful outcomes through our analysis of this thermo-circadian disruption caused by abnormal breast tissue (via morphological and endocrine factors) and the resulting dynamic temperature patterns.\n\nIn addition, we have completed the design of an iPhone application to transfer data from our collection device to the AI formulas operating in a cloud database environment.\n\nOur product team and strategic partners are adjusting our product plans to bring these realities into prototype testing and final production approvals. “The team is very energized by these new realities and working very diligently to build operations and customer capabilities to deliver a significantly new value proposition”, says Marly Heidkamp, COO.",
      "json_metadata": "{\"tags\":[\"cyrcadia\",\"health\",\"llbo\",\"ai\",\"advancements\"],\"links\":[\"http://cyrcadiahealth.com/may-14-2018-reno-nv-artificial-intelligence-advancements/\"],\"app\":\"steemit/0.1\",\"format\":\"markdown\"}"
    }
  ]
}

{
  "trx_id": "7be51b620629543eb69e2b6b663fa90657250592",
  "block": 22857726,
  "trx_in_block": 37,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-05-29T15:12:54",
  "op": [
    "comment",
    {
      "parent_author": "",
      "parent_permlink": "cyrcadia",
      "author": "squirrelnv",
      "permlink": "cyrcadia-health-roll-out-partnerships",
      "title": "Cyrcadia Health Roll-Out Partnerships",
      "body": "http://cyrcadiahealth.com/reno-nv-may-21-2018-key-partnerships-for-cyrcadia-health\n\nThree key partner relationships are in place to bring “Best of Breed” subject matter experts into the Cyrcadia Health, Go-To-Market sales launch plan:\n\nConsumer Marketing: Dupuis Marketing, Chicago: branding, packaging, social media advertising, and user experience design. “We develop and create business opportunities that establish new meaning for people–digging for deeper truths beyond commonly leveraged insights, evolving brand relevance and creating breakthrough products and services. We translate our clients’ business challenges into sustainable, responsible growth opportunities.”\n\nClinical Marketing: Life Sciences Strategy Group, San Jose: product visualization, product and market strategy. “Our approach employs best practices to align strategy with portfolio management and product development and commercialization processes. This integrated solution results in alignment of near, short and long–term planning cycles and development of strong and actionable marketing/brand, portfolio, new product, licensing and managed market strategies.”\n\nNerdy Dragon, Boise: IT infrastructure and web site management. “Nerdy Dragon is a connector and collaborative agency focused on digital asset design, production, and management. We deliver for clients – consistently, reliably, with world class quality and super-reasonable turnaround. We have designed and developed hundreds of web and app experiences since 2009. We are a team of over 300, located on 5 continents, working tirelessly to execute on digital projects – making, doing, connecting, and thriving. We have team members located in the US, South America, Australia, Asia, and Africa.”\n\n“Principals of these companies have been involved with Cyrcadia Health for a number of years and have a deep understanding of our value proposition to bring significant value to our Go-To-Market launch,” says Matt Benardis, CEO.\n\n“Their depth of experience in our markets means that “Best of Breed” strategies puts us in a market leadership position,” says Marly Heidkamp, COO.",
      "json_metadata": "{\"tags\":[\"cyrcadia\",\"health\",\"llbo\",\"roll-out\"],\"links\":[\"http://cyrcadiahealth.com/reno-nv-may-21-2018-key-partnerships-for-cyrcadia-health\"],\"app\":\"steemit/0.1\",\"format\":\"markdown\"}"
    }
  ]
}

{
  "trx_id": "49b52ec2b9e460ed90cb8ae4de15a954ad9f8392",
  "block": 22722452,
  "trx_in_block": 21,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-05-24T22:28:06",
  "op": [
    "comment",
    {
      "parent_author": "squirrelnv",
      "parent_permlink": "top-8-health-trends-in-hong-kong-for-2018-no-7",
      "author": "cheetah",
      "permlink": "cheetah-re-squirrelnvtop-8-health-trends-in-hong-kong-for-2018-no-7",
      "title": "",
      "body": "Hi! I am a robot. I just upvoted you! I found similar content that readers might be interested in:\nhttp://asiabiobank.com/healthy-matters-hong-kong/",
      "json_metadata": ""
    }
  ]
}

{
  "trx_id": "99ba3e8323a7336a21c26cc4af4acf9090a8881d",
  "block": 22722448,
  "trx_in_block": 16,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-05-24T22:27:54",
  "op": [
    "vote",
    {
      "voter": "cheetah",
      "author": "squirrelnv",
      "permlink": "top-8-health-trends-in-hong-kong-for-2018-no-7",
      "weight": 8
    }
  ]
}

{
  "trx_id": "0175267f2e411679be61d8e168c387b2fc563b84",
  "block": 22722433,
  "trx_in_block": 66,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-05-24T22:27:09",
  "op": [
    "comment",
    {
      "parent_author": "",
      "parent_permlink": "cyrcadia",
      "author": "squirrelnv",
      "permlink": "top-8-health-trends-in-hong-kong-for-2018-no-7",
      "title": "Top 8 Health Trends in Hong Kong for 2018... No. 7",
      "body": "https://www.healthymatters.com.hk/top-8-health-trends-hong-kong-2018\n\nTop 8 Health Trends in Hong Kong for 2018 | Exclusive Market Intel\nHealthy Matters announces its predictions for health in Hong Kong. Our editorial team has covered some exciting health trends for 2018 including massive doctor relocation, poop health, fat graft beauty surgery, fatherhood, self-care for woman, and much more!\n \n\n1 – Expect massive doctor relocation – Takshing House is closing\n​​\n\nIs your doctor located in Takshing House? Be prepared to go elsewhere! The building known to have housed hundreds of doctors for decades in their Central location on Des Voeux Road is set to close. Doctors and health practitioners will start to trickle out before the April 2019 deadline and will have to make some difficult decisions. Will they pay the big bucks to stay in Central where their patient base is? Will they head to more affordable neighbourhoods and risk losing patients? Or will they create a partnership with other practitioners? This is bound to shift the market of private care in Hong Kong.\n \n\n2 – Hong Kong’s first poop bank – yes, healthy stools is a thing now\n\n\nPoop is no laughing matter here. The Hong Kong based Asia Microbiota Bank which opened up earlier this year, is one of the first poop banks in Asia that supports fecal microbiota transplant procedures (FMT). Fecal transplant is a therapy that transfers gut microbes from healthy donors to sick patients that suffer from chronic gut conditions such as Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Ulcerative Colitis. The objective of FMT is to increase intestinal microbial diversity to reestablish a normal microbiome. In the US, the FDA allows physicians to use FMT for patients infected by Clostridium Difficile – an effective alternative to antibiotic resistance. As the scientific community is beginning to demonstrate that the bacteria in our gut plays a key role in our health, we will likely hear more about poop in the year ahead.\n \n\n3 – Too good to be true? Fat-grafting boosts your breast size with your unwanted fat\n​​\n\nWhat is fat grafting, you ask? Plastic surgeons have finally mastered the art of removing fat from one area (usually the lower abdomen or buttocks) and injecting it into another area of the body – the art of “grafting” fat. It is most effective in areas of the face that become sunken with age, usually around the cheeks, temples, or forehead. And what’s more, it can be used for breast augmentation. In recent years, cosmesis and sensation after surgery is further improved with new technologies such as water-assisted liposuction. We’ve seen the boom in natural products in the last few years, and here is plastic surgery’s answer to the call for “natural” options. As a word of caution, the results of fat grafting can be somewhat unpredictable and necessitate an expert hand.  Right now in Hong Kong, there are only a handful of such experts. Choosing a qualified plastic surgeon is of the utmost importance in HK where the beauty sector is scarcely regulated and has recently faced treatment blunders.\n \n\n4 – Focus on fatherhood – more dads asking for information on parenthood, their mental health and wellbeing​​\n\n\nMen are spending more time with their children and are becoming increasingly interested in seeking out parenthood tips, tricks and health advice. We have seen a growing number of men coming to Healthy Matters events and asking questions about health and parenthood (our “Tips for Daddies” session in October was packed!). We’ve scouted a couple of things we think are worth looking at for dads: Hong Kong Dads meeting up for playgroups; Australian organisation Beyond Blue providing some hilarious Dadvice; and local Hong Kong star, Lokyi Lai’s (黎諾懿) adorable videos with his son, including a dad and baby workout!\n \n\n5 – Self-care for women is becoming the norm, not a luxury​​\n\n\nAfter centuries of putting others first, women realize that looking after themselves is a necessity. It makes them a better friend, parent, spouse, colleague and a stronger family pillar. Investing in health and taking time to escape the pressures of fast-paced HK is becoming increasingly popular among women. As the world throws more at us, the importance of self-care for women is becoming the norm, not a luxury. Women will invest in annual medical check-ups and complementary medicines (naturopathy, traditional Chinese medicine, osteopathy, chiropractic). Women will also put the phone away, go for a walk, do an exercise class, have a massage or anything else that makes them feel good in 2018!\n \n\n6 – You will hear a lot more about Gleneagles Hospital​​\n\n\nLocated in Wong Chuk Hang, steps away from the Aberdeen Tunnel, Gleneagles Hospital is a brand-new hospital offering private services. Officially opened since March 2017, Gleneagles has some impressive credibility: they have partnered with the University of Hong Kong’s Medical School as their sole clinical partner; they are the only private hospital offering 24-hour Accident & Emergency services on Hong Kong Island; and when their obstetrics department opens in early 2018, it will be the only private hospital in Hong Kong with a Neonatal Intensive Care Unit. As their patient pool grows, you will be hearing a lot more about them.\n \n\n7 – HealthTech companies have their eyes on the HK market\n\n\nThe intersection of health and technology has just begun and it will dramatically change our way of consuming healthcare. As part of the StartmeupHK Festival 2018, HealthTech o2o is coming to Hong Kong on February 1st. We’ve got our eyes on a couple of interesting health technology innovations with products available in Hong Kong soon.\nThe ITBra by Cyrcadia is a discreet insert that fits into any bra to support early breast cancer detection. Currently breast cancer is the most common cancer in Hong Kong females, accounting for 26.1% of cancers in women. Considering there is no government-sponsored breast cancer screening program, we think the ITBra has a place in the Hong Kong health market.\nIn collaboration with the University of Waterloo’s (UoW) start-up incubator Velocity, O2 Canada has developed one of the world’s most effective, stylish and comfortable pollution masks. The masks have been tested extensively at the Air Pollution Innovation Lab at the UoW to provide superior protection from pollutants. They currently ship from Canada and are set to be sold on the Chinese market in January 2018. Read Healthy Matters’ interview with O2 Canada’s CEO and co-founder, Peter Whitby.\n \n\n8 – And there is more to come from Healthy Matters!​​\n\n\nWe are all about bringing Hong Kong-relevant health information and we have a lot of exciting things in store for 2018. In addition to providing trusted online health content, we are bringing you 2 unique event experiences: the 2nd Annual Kids Health + Parenting Event (June) and the 4th Annual Maternity + Baby Event (October). Check out 2017’s Maternity + Baby Event for a preview of what’s to come!\n \n\nStart your healthiest journey by liking our Facebook page and joining our community’s subscriber newsletter now!",
      "json_metadata": "{\"tags\":[\"cyrcadia\",\"health\",\"asia\",\"lifeline\",\"llbo\"],\"links\":[\"https://www.healthymatters.com.hk/top-8-health-trends-hong-kong-2018\"],\"app\":\"steemit/0.1\",\"format\":\"markdown\"}"
    }
  ]
}

{
  "trx_id": "14dd219fb7c2bc137af8a5f1b417577e2311a5d1",
  "block": 22722323,
  "trx_in_block": 39,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-05-24T22:21:39",
  "op": [
    "comment",
    {
      "parent_author": "",
      "parent_permlink": "cyrcadia",
      "author": "squirrelnv",
      "permlink": "chris-bailey-cyrcadia-asia-o2o-youtube",
      "title": "Chris Bailey Cyrcadia Asia O2O YouTube",
      "body": "https://www.youtube.com/watch?v=8MqSsmI0E-A",
      "json_metadata": "{\"tags\":[\"cyrcadia\",\"health\",\"asia\",\"youtube\"],\"image\":[\"https://img.youtube.com/vi/8MqSsmI0E-A/0.jpg\"],\"links\":[\"https://www.youtube.com/watch?v=8MqSsmI0E-A\"],\"app\":\"steemit/0.1\",\"format\":\"markdown\"}"
    }
  ]
}

{
  "trx_id": "68a7369f0af7f76f07bf6e1bbb4f31e2cee5057b",
  "block": 22722244,
  "trx_in_block": 7,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-05-24T22:17:42",
  "op": [
    "vote",
    {
      "voter": "ubg",
      "author": "squirrelnv",
      "permlink": "cyrcadia-go-to-market-news",
      "weight": 100
    }
  ]
}

{
  "trx_id": "32610ecce9b784ad7a80164618e0323756a6940a",
  "block": 22722229,
  "trx_in_block": 31,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-05-24T22:16:57",
  "op": [
    "comment",
    {
      "parent_author": "squirrelnv",
      "parent_permlink": "cyrcadia-go-to-market-news",
      "author": "cheetah",
      "permlink": "cheetah-re-squirrelnvcyrcadia-go-to-market-news",
      "title": "",
      "body": "Hi! I am a robot. I just upvoted you! I found similar content that readers might be interested in:\nhttp://cyrcadiahealth.com/management/",
      "json_metadata": ""
    }
  ]
}

{
  "trx_id": "c47aa8653bb3c671ba62b23bf1d55eccc1933487",
  "block": 22722227,
  "trx_in_block": 16,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-05-24T22:16:51",
  "op": [
    "vote",
    {
      "voter": "cheetah",
      "author": "squirrelnv",
      "permlink": "cyrcadia-go-to-market-news",
      "weight": 8
    }
  ]
}

{
  "trx_id": "50aba20d9493991e35367bfb6de7f7a8bb8a7978",
  "block": 22722224,
  "trx_in_block": 27,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-05-24T22:16:42",
  "op": [
    "vote",
    {
      "voter": "ax3",
      "author": "squirrelnv",
      "permlink": "cyrcadia-go-to-market-news",
      "weight": 100
    }
  ]
}

{
  "trx_id": "eb4ec314c825b9d51beec6e7fbac7eefec45c1f1",
  "block": 22722218,
  "trx_in_block": 12,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-05-24T22:16:24",
  "op": [
    "comment",
    {
      "parent_author": "",
      "parent_permlink": "cyrcadia",
      "author": "squirrelnv",
      "permlink": "cyrcadia-go-to-market-news",
      "title": "Cyrcadia Go-To Market News",
      "body": "May 4, 2018, Reno, NV. Expanded Go-To-Market Team\n\nby admin | May 4, 2018 | News | 0 comments\nMay 4, 2018, Reno, NV. Expanded Go-To-Market Team \n\nCyrcadia, Inc. is pleased to announce the addition of Marly Heidkamp, Chief Operating Officer,\n R.N., MSEd to the executive team to focus on execution of the Go-to- Market plan.\n\nJim Holmes, CFO, say, “We are pleased to have an operations executive join our team who possesses\n medical product management experience as well. We are confident her leadership will bring added\n perspective to a product targeted for the female population.” Matt Benardis, CEO, added “We have\n already seen results from her leadership of the recent kick-off meeting with the comprehensive\n Go-To- Market team and her engagement of each department regarding oversight, organization and\n accountability.” Please see the attached Team photo from a very successful kick-off.\n\nMarly brings over 30 years of healthcare and corporate operations depth, as well as consulting and\n management experience to our team. Her career also includes experience as a pediatrics and specialty\n care nursery nurse.\n\nConsulting lessons learned include experience in Healthcare, Big Four, Fortune 500 professional services\n and software environments, plus co-founding and managing a boutique management consulting\n business for over 10 years.\n\nMs. Heidkamp’s operations experience in healthcare and software environments include leadership\n roles in electronic health records software, healthcare consulting, hospital-wide training and education,\n vendor credentialing program and software for hospitals, hospital business transformation, strategic\n planning and execution and customer loyalty programs.\n\nHer educational background includes Masters of Science in Adult Learning, with emphasis in\n Organizational Development, Instructional Design and Change Management (Northern Illinois\n University in DeKalb, IL), Bachelor of Science in Nursing (Benedictine University, Lisle, IL) and\n Certificate in Leading People, Leading Organizations (USC Marshall School of Business).\n\nPlease join us in welcoming Marly to our exciting launch team.\n\nMarly Heidkamp\n [email protected]",
      "json_metadata": "{\"tags\":[\"cyrcadia\",\"health\",\"lifeline\",\"llbo\"],\"app\":\"steemit/0.1\",\"format\":\"markdown\"}"
    }
  ]
}

{
  "trx_id": "ea54e128e40ebe3d66e24833200c9afa84bbc121",
  "block": 21771350,
  "trx_in_block": 56,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-04-21T20:53:06",
  "op": [
    "delegate_vesting_shares",
    {
      "delegator": "steem",
      "delegatee": "squirrelnv",
      "vesting_shares": "29534.879354 VESTS"
    }
  ]
}

{
  "trx_id": "40e60eaec2db3bc0eb934658fc352ed4c17b59e4",
  "block": 21262605,
  "trx_in_block": 46,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-04-04T04:52:12",
  "op": [
    "vote",
    {
      "voter": "squirrelnv",
      "author": "mttraderguy",
      "permlink": "the-end-of-breast-cancer-please-read-and-share",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "2ca36c316b9ed1f39408e88319accc8e0673ba5d",
  "block": 21262586,
  "trx_in_block": 17,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-04-04T04:51:15",
  "op": [
    "custom_json",
    {
      "required_auths": [],
      "required_posting_auths": [
        "squirrelnv"
      ],
      "id": "follow",
      "json": "[\"follow\",{\"follower\":\"squirrelnv\",\"following\":\"mttraderguy\",\"what\":[\"blog\"]}]"
    }
  ]
}

{
  "trx_id": "5a2790a5c9d5c0d6ff1f8c2be21e87081db3289b",
  "block": 21222148,
  "trx_in_block": 23,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-04-02T19:09:03",
  "op": [
    "custom_json",
    {
      "required_auths": [],
      "required_posting_auths": [
        "squirrelnv"
      ],
      "id": "follow",
      "json": "[\"follow\",{\"follower\":\"squirrelnv\",\"following\":\"buddy67\",\"what\":[]}]"
    }
  ]
}

{
  "trx_id": "f4e8c69bbdc58fa6f7a5e73656ec861cd9fcf807",
  "block": 20287065,
  "trx_in_block": 71,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-03-01T06:42:09",
  "op": [
    "vote",
    {
      "voter": "eshurin",
      "author": "squirrelnv",
      "permlink": "cyrcadia-health-2018-update",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "9aeec65eff991dea0be49b5d2fffe8018e68726a",
  "block": 20277770,
  "trx_in_block": 1,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-02-28T22:56:57",
  "op": [
    "vote",
    {
      "voter": "sensation",
      "author": "squirrelnv",
      "permlink": "cyrcadia-health-2018-update",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "284059ccf283cccf236402340b526cd64b5cd0c8",
  "block": 20275089,
  "trx_in_block": 8,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-02-28T20:42:51",
  "op": [
    "vote",
    {
      "voter": "moby-dick",
      "author": "squirrelnv",
      "permlink": "cyrcadia-health-2018-update",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "876e70e3a4207d1edc088f8850ea8ce50e543a7e",
  "block": 20274608,
  "trx_in_block": 40,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-02-28T20:18:48",
  "op": [
    "comment",
    {
      "parent_author": "squirrelnv",
      "parent_permlink": "lifeline-biotechnologies-2018-update",
      "author": "cheetah",
      "permlink": "cheetah-re-squirrelnvlifeline-biotechnologies-2018-update",
      "title": "",
      "body": "Hi! I am a robot. I just upvoted you! I found similar content that readers might be interested in:\nhttp://www.walb.com/story/37611733/lifeline-biotechnologies-provides-information-to-the-public-and-its-shareholders",
      "json_metadata": ""
    }
  ]
}

{
  "trx_id": "0ca3fe75c62b43531eacdf7a2848a6ef9a6e7e2d",
  "block": 20274607,
  "trx_in_block": 32,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-02-28T20:18:45",
  "op": [
    "vote",
    {
      "voter": "cheetah",
      "author": "squirrelnv",
      "permlink": "lifeline-biotechnologies-2018-update",
      "weight": 8
    }
  ]
}

{
  "trx_id": "97eb660e8a2b157829fb805c85d814e93bf0c774",
  "block": 20274604,
  "trx_in_block": 8,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-02-28T20:18:36",
  "op": [
    "comment",
    {
      "parent_author": "",
      "parent_permlink": "lifeline",
      "author": "squirrelnv",
      "permlink": "lifeline-biotechnologies-2018-update",
      "title": "Lifeline Biotechnologies 2018 Update",
      "body": "Reno, NV , Feb. 28, 2018 (GLOBE NEWSWIRE) --\n\nLifeline Biotechnologies, Inc, (“The Company”) (OTC PINK: LLBO) Provides Information to the Public and Updates It’s Shareholders.\n\nIn 2017 Lifeline transferred its previously licensed technology and patents to its affiliate, Cyrcadia, Inc. in exchange for additional equity in Cyrcadia, cash and a promissory note.\n\nAs a result of the Lifeline became Cyrcadia’s largest, single shareholder at approximately 40%. At that time the transaction was valued at over twelve million dollars.\n\nSubsequently, Cyrcadia, Inc. licensed Cyrcadia Asia to further develop and finance product upgrades to Cyrcadia, Inc.’s basic capabilities.  The increased capabilities include updated and current state of the art technology and efficiencies.  These upgrades are nearing completion and product is forecast, by vendors, to be market ready and available by mid-2018.  The clinical trials Cyrcadia, Inc. has been  conducting at El Camino Hospital and Ohio State University’s Cancer Center, were approximately one-third completed, will be resumed upon product availability, and continued until completion.  There have been several positive outcomes derived from the one third completion of the trials, those outcomes, which cannot be described here due to FDA regulations, indicate the trials may be able to be completed in a shorter period of time than originally estimated, possibly completed later this year?\n\nCyrcadia, Inc. management, in addition to the clinical market potential, has been investigating consumer market opportunities for it early tissue abnormality identification technology.  Cyrcadia has retained two medical marketing consulting firms to explore, determine and validate consumer adoption and market potential of its consumer product.\n\nJim Holmes, Lifeline’s CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product.  Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs.  We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer.  The cost savings was estimated at over $300,000 per patient.  Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually.     \n\nCurrent and futures News updates, posted on CI’s website: cyrcadiahealth.com and under “News” will be posted on Lifeline’s Cyrcadia/News.\n\nSafe Harbor Statement:  \n\nThis release includes forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995.   Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions",
      "json_metadata": "{\"tags\":[\"lifeline\",\"cyrcadia\",\"health\",\"breast\",\"cancer\"],\"app\":\"steemit/0.1\",\"format\":\"markdown\"}"
    }
  ]
}

{
  "trx_id": "9453e51763773d676f0ddfcf72a320ad678b2092",
  "block": 20274411,
  "trx_in_block": 11,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-02-28T20:08:54",
  "op": [
    "comment",
    {
      "parent_author": "",
      "parent_permlink": "cyrcadia",
      "author": "squirrelnv",
      "permlink": "cyrcadia-health-2018-update",
      "title": "Cyrcadia Health 2018 Update",
      "body": "Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter\n\nby admin | Feb 21, 2018 | News | 0 comments\n\n\nFebruary 27, 2018\n\nCyrcadia, Inc. (“CI”) extends its thanks and appreciation in your interest and support of our endeavors. We are taking this opportunity to provide an update, as well as apprise you of upcoming expectations.\n\nLicense and Cooperation Agreement with Cyrcadia Asia (“CA”) – Status \n Earlier in 2017 CI entered into an Agreement with CA, whereby CA assumed the responsibility and funding of the design, development and delivery of a scalable, commercializable iTBra™ system including upgraded hardware and the full suite of application software as well as automation of our proprietary Artificial Intelligence Analytics. The estimated cost of development with Jabil and Mobile Now is approximately $1.2 to $1.5 million US. As such, the agreement calls for CA to provide timely reporting and status of product development including timelines, milestones and dates of completion and delivery of product (market readiness, product volume availability and delivery terms and schedules). \n\nMany strides have been made in the evolution of the relationship as CA has established its operations, initial staffing and funding. Both CI and CA are in a mode of cooperation, as called for by the Agreement and, presently, both entities are to hold routine meetings where comprehensive updating and reporting will be delivered to CI, enabling implementation of our business, operations and marketing plans. We will be reporting the outcomes of that meeting to move forward on our ability to commercialize the iTBra™ system this year. \n\nGiven the above, we would like to update on the internal operations that will allow for CI to “hit the ground running” upon product delivery.\n\nStatus of Product Development and Manufacturing\n\nUnder CA’s contract with Jabil for the design, development and manufacturing for both entities, CI and CA and according to CA, the development schedule is on track and both CI and CA are expecting functional prototype units for clinical study and market applications in the second half of 2018. Jabil has moved through various levels of development including Engineering Validation (EV) and Design Validation (DV) with Design Verification Testing and Product Compliance Testing as the next and final tasks. From there, the product is released for production (MP Release).\n\n\n\nJabil will manufacture the iTBra™ as the initial vendor for both CI and CA (both companies operating under the global head brand of Cyrcadia Health) hardware at their FDA-approved facility in Shanghai. Full scale manufacturing is scheduled to start in the second half 2018, but in the intervening period, we will be able to obtain fully functional products for pilot launches in the U.S. and other countries.\n\nCA’s other contracted developer, Mobile Now Group, is well down the road of development and testing of the “front end” software application and User Interface (UI). Outcomes of the CA/CI cooperation meetings will provide precise status of development along with timelines and schedules. \n\n\n *Prototype example of User Interface Screens\n\nRegulatory Clearance, Trials Recap\n\nCI’s current US trial success has allowed us to utilize a Non-Filing Justification (NFJ) with the FDA, under our current FDA 510(k) Class II clearance, enabling CI to go to market. Additionally, CI and CA have contracted with two regulatory advisor contractors to drive to a Class I designation (Over the Counter and direct to consumer markets) allowing for entry into market without the scrutiny of a class II device (Clinical, prescribed by physician market), as the iTBra™ stands now. The intent is launch into both the consumer and Over the Counter (OTC) markets almost simultaneously with the clinical markets. Thus far, indications are favorable for this approach and we will be meeting directly with the FDA in the months to come, declaring our intent. We will report again on the meeting outcomes once definitive. Moreover, CI will pursue a Modified 510(k) through the FDA enabling the rapid expansion of the clinical markets. This does not preclude us from going to market with our existing 510(k), Class II clearance (see the NFJ position above), but will certainly enhance our visibility and buy-in from the medical/clinical community. \n\nThe El Camino Hospital and The Ohio State University clinical trials have shown that CI’s scalable device is demonstrating over 84% accuracy, sensitivity and specificity with a 2-hour wear time, vs. the Chronodynamic’s (First Warning System) historic accuracy of 74.5% and a required 48-hour wear time. CI has reengaged with El Camino Hospital to resume (pending CA’s timely product delivery) the paused clinical trials with the new and significantly improved commercializable product. Discussions are underway with the other trial site, The James Cancer center at Ohio State University, to resume the paused trials under the new product design and protocol. A.\n\nIntellectual Property\n\nSince the original CI patents were issued in 2012, the product and artificial intelligence based software has evolved considerably into the wearable and conformable device that it is now. Invention disclosers have been completed and are currently under review by both CI and CA intellectual property counsels. As a result, both CI and CA will own several new patent applications. Those applications can take some years to be examined and approved, but the pending patents themselves will have tangible value to current and potential investors, partners and acquirers. As a result of the deal with CA, CA is also applying for trademarks, designs and patents in multiple countries in the US and Asia, to be assigned to territories that CI serves. \n\nOperations\n\nCI and CA are currently structuring a detailed supply agreement for product delivery including the terms, costs and volumes with timing. Jabil will be a critical element of this agreement and is preparing to collaborate with both CI and CA as the manufacturer on delivery of goods for marketing and sales. This agreement is a critical piece and a significant milestone to realize the conversion to market from design and development. We will deliver more detailed information once the agreement is completed and consummated.\n\nCI is expanding its team with contractors and internal additions. We have retained two groups for marketing/commercialization addressing the consumer/OTC markets: Life Science Strategy Group (LSSG) and the DuPuis Group. LSSG has performed extensive, third party market research for positioning and roll out to the clinical markets. The DuPuis Group has performed deep market research specifically to the consumer/OTC markets, and, as you will see below, has been selected as our strategic partner for commercialization and marketing deployment in the consumer/OTC markets.\n For the clinical markets, CI is in discussions with potential strategic partners for the marketing deployment and commercialization for the clinical markets. We will share more in depth information once we have selected that strategic partner.\n\nCI has retained consultant Cheryl Fisher, formerly with the Emergo Group, as our internal Director of Regulatory Affairs, Quality Assurance, and Clinical Affairs (RA/QA/CA). Mrs. Fisher will operate as the conduit between CI and the FDA, as well as manage and guide our Regulatory pathway as described above. Cheryl has worked with the company in an advisory capacity for a number of years and has deep knowledge and familiarity of not only the FDA requirements and processes, but with CI itself.\n\nFinally, CI has retained a consultant to drive the comprehensive processes and agendas currently under way, fulfilling the need for timely execution, team and department accountability, as well as risk management and reporting to the executive team.\n\nMore headcount is slated as we prepare to execute our marketing plans. We will introduce you to those capable team members as they come aboard.\n\nClinical Market Pilots and Market Entry\n\nAs previously noted, the first clinical market entries are likely to be with insurance partners working through CA in Asia (and by extension, CI in the U.S.). CI will also launch a lead out pilot in the U.S through Evidation Health (see evidation.com) and its affiliates, Dignity Health and Kaiser Permanente. Evidation, associated with Stanford University and funded by GE Ventures and others, evaluates how the evolution of digital health and wearables can affect change from a care and insurance perspective in the U.S. Through Evidation, the pilot launch will involve a nominal number of subjects with a rapid pace of subscription and validation to both publish and allow leading healthcare providers, insurers and key opinion leaders to observe the value and marketability of the CI solution. This relationship and process provides rapid exposure to the caliber of the business partners and associates of Evidation that would otherwise take years to achieve. These relationships are key to expediting mandates to participants of the insurers and healthcare networks without CI’s need for significant staffing and fundraising to develop an internal salesforce within CI.\n\nOTC and Consumer Commercialization\n\nOur priority now is to finalize and implement our marketing plan enabling the ramp up of sales as soon as possible in 2018 upon product delivery.\n We are pleased to report the contracting of the DuPuis Group to implement and execute the OTC/Consumer commercialization plan to put “product on the shelves.” This has been a significant gap for us and their familiarity and deep knowledge of our value proposition is unparalleled. They are an exemplary team to bring us to revenue. More to come as we develop our timing and targets for rollout. \n\nCompetitive Analysis\n\nNo competitive technologies have materialized that would threaten our business plan. We are confident our intellectual property filings are a significant barrier to market entry and our usage of artificial intelligence software is market leading technology. In addition, our contract for manufacturing in China ensures a high volume competitive product cost.\n\nOn behalf of the Cyrcadia, Inc. team, we thank you for your support as we bring this life saving technology to market. We will make every effort to ensure timely and profitable delivery of CI’s technology to the U.S. market and rest of world outside of the territories covered by CA. We are committed to ensuring ongoing communication and look forward to demonstrating further success in 2018 and beyond.\n\nSincerely,\n\nMatt Benardis\n CEO\n Cyrcadia, Inc.",
      "json_metadata": "{\"tags\":[\"cyrcadia\",\"health\",\"lifeline\",\"breast\",\"cancer\"],\"app\":\"steemit/0.1\",\"format\":\"markdown\"}"
    }
  ]
}

{
  "trx_id": "789b77adc2f765e047d3f7adfb08e0ba278a5e10",
  "block": 20273138,
  "trx_in_block": 15,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-02-28T19:05:09",
  "op": [
    "vote",
    {
      "voter": "squirrelnv",
      "author": "skytronia",
      "permlink": "12-laughing-my-ass-off-big-time-some-of-my-favorite-quotes-jokes-motivation-facts-and-true-stories-during-my-life-time",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "980624ee443cb0d36184698ede03a403056a8b23",
  "block": 20273067,
  "trx_in_block": 55,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-02-28T19:01:36",
  "op": [
    "vote",
    {
      "voter": "squirrelnv",
      "author": "kylo",
      "permlink": "dango-i-love-shiba-s",
      "weight": 10000
    }
  ]
}

{
  "trx_id": "c5f39fa87a5f1c87d2e030faa9329d13126dd637",
  "block": 18601629,
  "trx_in_block": 6,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2018-01-01T16:47:54",
  "op": [
    "custom_json",
    {
      "required_auths": [],
      "required_posting_auths": [
        "squirrelnv"
      ],
      "id": "follow",
      "json": "[\"follow\",{\"follower\":\"squirrelnv\",\"following\":\"buddy67\",\"what\":[\"blog\"]}]"
    }
  ]
}

{
  "trx_id": "972840e51ef5223844fec65e0c98f7c4a5c08c0c",
  "block": 18490194,
  "trx_in_block": 13,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2017-12-28T19:49:48",
  "op": [
    "custom_json",
    {
      "required_auths": [],
      "required_posting_auths": [
        "squirrelnv"
      ],
      "id": "follow",
      "json": "[\"follow\",{\"follower\":\"squirrelnv\",\"following\":\"fabinhocrypto\",\"what\":[\"blog\"]}]"
    }
  ]
}

{
  "trx_id": "6d6b487535dd985171c6eb5710d4c2e5d2dba8bf",
  "block": 18468369,
  "trx_in_block": 5,
  "op_in_trx": 0,
  "virtual_op": 0,
  "timestamp": "2017-12-28T01:37:57",
  "op": [
    "custom_json",
    {
      "required_auths": [],
      "required_posting_auths": [
        "squirrelnv"
      ],
      "id": "follow",
      "json": "[\"follow\",{\"follower\":\"squirrelnv\",\"following\":\"vivekkanade\",\"what\":[\"blog\"]}]"
    }
  ]
}